NO3004110T3 - - Google Patents
Info
- Publication number
- NO3004110T3 NO3004110T3 NO14731799A NO14731799A NO3004110T3 NO 3004110 T3 NO3004110 T3 NO 3004110T3 NO 14731799 A NO14731799 A NO 14731799A NO 14731799 A NO14731799 A NO 14731799A NO 3004110 T3 NO3004110 T3 NO 3004110T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13169364 | 2013-05-27 | ||
| EP13177673 | 2013-07-23 | ||
| EP14731799.4A EP3004110B1 (en) | 2013-05-27 | 2014-05-26 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| PCT/IB2014/061717 WO2014191896A1 (en) | 2013-05-27 | 2014-05-26 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3004110T3 true NO3004110T3 (es) | 2017-12-23 |
Family
ID=50979827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14731799A NO3004110T3 (es) | 2013-05-27 | 2014-05-26 |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8975417B2 (es) |
| EP (1) | EP3004110B1 (es) |
| JP (1) | JP6181862B2 (es) |
| KR (1) | KR20160012196A (es) |
| CN (1) | CN105408335B (es) |
| AU (1) | AU2014272776C1 (es) |
| BR (1) | BR112015029512A8 (es) |
| CA (1) | CA2913223A1 (es) |
| CL (1) | CL2015003395A1 (es) |
| CR (1) | CR20150628A (es) |
| CU (1) | CU24350B1 (es) |
| CY (1) | CY1119490T1 (es) |
| DK (1) | DK3004110T3 (es) |
| EA (1) | EA029515B1 (es) |
| EC (1) | ECSP15053445A (es) |
| ES (1) | ES2651843T3 (es) |
| HK (1) | HK1216251A1 (es) |
| HR (1) | HRP20171613T1 (es) |
| HU (1) | HUE036674T2 (es) |
| IL (1) | IL242610A0 (es) |
| LT (1) | LT3004110T (es) |
| ME (1) | ME02906B (es) |
| MX (1) | MX364205B (es) |
| NO (1) | NO3004110T3 (es) |
| PE (1) | PE20160005A1 (es) |
| PH (2) | PH12015502628A1 (es) |
| PL (1) | PL3004110T3 (es) |
| PT (1) | PT3004110T (es) |
| RS (1) | RS56522B1 (es) |
| SG (1) | SG11201509474SA (es) |
| SI (1) | SI3004110T1 (es) |
| SV (1) | SV2015005115A (es) |
| TN (1) | TN2015000505A1 (es) |
| UA (1) | UA116017C2 (es) |
| UY (1) | UY35586A (es) |
| WO (1) | WO2014191896A1 (es) |
| ZA (1) | ZA201508259B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| KR20150096794A (ko) | 2012-12-21 | 2015-08-25 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물 |
| EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| UA119848C2 (uk) | 2013-03-15 | 2019-08-27 | Інсайт Холдинґс Корпорейшн | Трициклічні гетероцикли як інгібітори білків бет |
| PL3004108T3 (pl) * | 2013-05-28 | 2018-03-30 | Novartis Ag | Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób |
| ES2661437T3 (es) | 2013-06-21 | 2018-04-02 | Zenith Epigenetics Corp. | Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio |
| SG10201710705UA (en) | 2013-06-21 | 2018-02-27 | Zenith Epigenetics Ltd | Novel bicyclic bromodomain inhibitors |
| WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EA201690087A1 (ru) | 2013-07-31 | 2016-08-31 | Зенит Эпидженетикс Корп. | Новые квиназолиноны как ингибиторы бромодомена |
| PE20180248A1 (es) | 2013-10-18 | 2018-02-02 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| EP3674302B1 (en) | 2014-04-23 | 2023-03-01 | Incyte Holdings Corporation | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
| WO2016087942A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridines as bromodomain inhibitors |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| WO2017024406A1 (en) | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| AU2016305513A1 (en) | 2015-08-11 | 2018-03-08 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| MX2018001756A (es) | 2015-08-12 | 2018-09-06 | Neomed Inst | Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos. |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
| WO2017127930A1 (en) * | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| CA3013988A1 (en) | 2016-02-15 | 2017-08-24 | Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh | Taf1 inhibitors for the therapy of cancer |
| WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
| TW201803594A (zh) * | 2016-06-09 | 2018-02-01 | 達納-法伯癌症協會 | Hdac抑制劑與bet抑制劑之使用方法及醫藥組合 |
| KR102643344B1 (ko) | 2016-06-20 | 2024-03-07 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
| PL3486242T3 (pl) | 2016-08-31 | 2022-03-21 | Jiangsu Hengrui Medicine Co. Ltd. | Pochodna oksopikolinamidu, sposób jej wytwarzania i zastosowanie farmaceutyczne |
| MX2019005443A (es) | 2016-11-14 | 2019-11-21 | Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh | Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer. |
| CN109232301B (zh) * | 2018-10-15 | 2021-01-01 | 天津希恩思生化科技有限公司 | 一种四异丙基肼的制备方法 |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| KR20220054293A (ko) * | 2019-07-12 | 2022-05-02 | 시닉 이뮤놀러지 비.브이. | Isoqc 및/또는 qc 효소의 억제제로서 n-치환된-3,4-(융합된 5-환)-5-페닐-피롤리딘-2-온 화합물 |
| CN114502534A (zh) | 2019-09-30 | 2022-05-13 | 协和麒麟株式会社 | Bet降解剂 |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| JP2024507672A (ja) * | 2021-01-21 | 2024-02-21 | ベイジン・ティアンタン・ホスピタル | Ｆｐｒ１のモジュレーター及びそれを使用する方法 |
| KR20240042609A (ko) | 2021-08-02 | 2024-04-02 | 신젠타 크롭 프로텍션 아게 | 살미생물 피라졸 유도체 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN118368986A (zh) | 2021-12-17 | 2024-07-19 | 先正达农作物保护股份公司 | 杀微生物的吡唑衍生物 |
| KR20250019076A (ko) | 2022-05-30 | 2025-02-07 | 아도알엑스 테라퓨틱스 리미티드 | Cd73 억제제 화합물 |
| TW202430514A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| TW202435758A (zh) | 2023-01-27 | 2024-09-16 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| TW202434112A (zh) | 2023-02-01 | 2024-09-01 | 瑞士商先正達農作物保護股份公司 | 殺真菌組成物 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2024256438A1 (en) | 2023-06-14 | 2024-12-19 | Syngenta Crop Protection Ag | Fungicidal compositions |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508300A (en) | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
| DK1320531T3 (da) | 2000-08-10 | 2011-01-03 | Pfizer Italia Srl | Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse |
| PT1397364E (pt) * | 2001-05-24 | 2007-10-22 | Lilly Co Eli | Novos derivados de pirrole como agentes farmacêuticos |
| RU2305095C2 (ru) | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003235504A1 (en) | 2002-05-13 | 2003-11-11 | 3-Dimensional Pharmaceuticals, Inc. | Method for cytoprotection through mdm2 and hdm2 inhibition |
| KR100832277B1 (ko) | 2004-05-18 | 2008-05-26 | 에프. 호프만-라 로슈 아게 | 신규 ｃｉｓ-이미다졸린 |
| US20060069085A1 (en) | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| EP1833807A1 (en) | 2005-01-05 | 2007-09-19 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| AU2006326063B2 (en) | 2005-12-12 | 2012-07-19 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors |
| WO2007096334A1 (en) | 2006-02-24 | 2007-08-30 | Pfizer Italia Srl | Pyrrolopyrrolones active as kinase inhibitors |
| US8367699B2 (en) | 2006-09-15 | 2013-02-05 | Nexuspharma, Inc. | Tetrahydro-isoquinolines |
| JP5624762B2 (ja) | 2007-03-30 | 2014-11-12 | 塩野義製薬株式会社 | 新規ピロリノン誘導体およびそれを含有する医薬組成物 |
| EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| EP2336109A4 (en) | 2008-09-25 | 2012-05-02 | Shionogi & Co | NOVEL PYRROLINONE DERIVATIVE AND DRUG COMPOSITION CONTAINING THE SAME |
| WO2010141738A2 (en) | 2009-06-03 | 2010-12-09 | President And Fellows Of Harvard College | Compositions and method for inhibiting tumor growth |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JP5913292B2 (ja) * | 2010-05-14 | 2016-04-27 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 代謝を調節する組成物および方法 |
| JP5844358B2 (ja) | 2010-06-22 | 2016-01-13 | グラクソスミスクライン エルエルシー | ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤 |
| US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
| GB201016880D0 (en) | 2010-10-07 | 2010-11-17 | Riotech Pharmaceuticals Ltd | Phosphodiesterase inhibitors |
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
| EP2721008B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors |
| GB2492950A (en) | 2011-07-11 | 2013-01-23 | Cambridge Consultants | Measuring a luminescent property of a sample using a dual-modulated excitation beam |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| CN104080787B (zh) | 2011-11-29 | 2016-09-14 | 诺华股份有限公司 | 吡唑并吡咯烷化合物 |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
-
2014
- 2014-05-20 US US14/282,515 patent/US8975417B2/en active Active
- 2014-05-26 HU HUE14731799A patent/HUE036674T2/hu unknown
- 2014-05-26 CN CN201480042021.8A patent/CN105408335B/zh not_active Expired - Fee Related
- 2014-05-26 UY UY0001035586A patent/UY35586A/es not_active Application Discontinuation
- 2014-05-26 TN TN2015000505A patent/TN2015000505A1/en unknown
- 2014-05-26 CU CUP2015000163A patent/CU24350B1/es unknown
- 2014-05-26 JP JP2016516277A patent/JP6181862B2/ja not_active Expired - Fee Related
- 2014-05-26 RS RS20171074A patent/RS56522B1/sr unknown
- 2014-05-26 KR KR1020157036225A patent/KR20160012196A/ko not_active Ceased
- 2014-05-26 PL PL14731799T patent/PL3004110T3/pl unknown
- 2014-05-26 UA UAA201510962A patent/UA116017C2/uk unknown
- 2014-05-26 DK DK14731799.4T patent/DK3004110T3/da active
- 2014-05-26 AU AU2014272776A patent/AU2014272776C1/en not_active Ceased
- 2014-05-26 SI SI201430425T patent/SI3004110T1/sl unknown
- 2014-05-26 EP EP14731799.4A patent/EP3004110B1/en active Active
- 2014-05-26 CA CA2913223A patent/CA2913223A1/en not_active Abandoned
- 2014-05-26 BR BR112015029512A patent/BR112015029512A8/pt not_active Application Discontinuation
- 2014-05-26 PT PT147317994T patent/PT3004110T/pt unknown
- 2014-05-26 PE PE2015002539A patent/PE20160005A1/es not_active Application Discontinuation
- 2014-05-26 MX MX2015016416A patent/MX364205B/es active IP Right Grant
- 2014-05-26 EA EA201592250A patent/EA029515B1/ru not_active IP Right Cessation
- 2014-05-26 ME MEP-2017-248A patent/ME02906B/me unknown
- 2014-05-26 SG SG11201509474SA patent/SG11201509474SA/en unknown
- 2014-05-26 NO NO14731799A patent/NO3004110T3/no unknown
- 2014-05-26 ES ES14731799.4T patent/ES2651843T3/es active Active
- 2014-05-26 LT LTEP14731799.4T patent/LT3004110T/lt unknown
- 2014-05-26 WO PCT/IB2014/061717 patent/WO2014191896A1/en active Application Filing
- 2014-05-26 US US14/892,613 patent/US20160095843A1/en not_active Abandoned
-
2015
- 2015-11-09 ZA ZA2015/08259A patent/ZA201508259B/en unknown
- 2015-11-16 IL IL242610A patent/IL242610A0/en unknown
- 2015-11-19 CL CL2015003395A patent/CL2015003395A1/es unknown
- 2015-11-25 PH PH12015502628A patent/PH12015502628A1/en unknown
- 2015-11-27 CR CR20150628A patent/CR20150628A/es unknown
- 2015-11-27 SV SV2015005115A patent/SV2015005115A/es unknown
- 2015-12-22 EC ECIEPI201553445A patent/ECSP15053445A/es unknown
-
2016
- 2016-04-13 HK HK16104211.7A patent/HK1216251A1/zh not_active IP Right Cessation
-
2017
- 2017-10-24 HR HRP20171613TT patent/HRP20171613T1/hr unknown
- 2017-10-25 CY CY20171101108T patent/CY1119490T1/el unknown
-
2018
- 2018-08-24 PH PH12018501807A patent/PH12018501807A1/en unknown